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Accepted 16 January 2009AbstractObjective: The lack of a standard methodology in diagnostic research impedes adequate evaluation before implementation of con-
stantly developing diagnostic techniques. We discuss the methodology of diagnostic research and underscore the relevance of decision anal-
ysis in the process of evaluation of diagnostic tests.
Study Design and Setting: Overview and conceptual discussion.
Results: Diagnostic research requires a stepwise approach comprising assessment of test characteristics followed by evaluation of added
value, clinical outcome, and cost-effectiveness. These multiple goals are generally incompatible with a randomized design. Decision-
analytic models provide an important alternative through integration of the best available evidence. Thus, critical assessment of clinical
value and efficient use of resources can be achieved.
Conclusion: Decision-analytic models should be considered part of the standard methodology in diagnostic research. They can serve as
a valid alternative to diagnostic randomized clinical trials (RCTs).  2009 Elsevier Inc. All rights reserved.
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To date, consensus on the methodology to evaluate new
diagnostic tests is lacking [1]. Moreover, with rapid techni-
cal advances, especially in the field of imaging, diagnostic
techniques undergoing evaluation may be already outdated
before diagnostic and clinical values are established [2,3].
Similar to therapeutic research, a hierarchy can be dis-
cerned within diagnostic research [1,2,4e7]. The first step
is the assessment of test characteristics of a new test. The
next step is the evaluation of its added value [8]. The third
step is the assessment of the effect on clinical outcome, and
the final step comprises a cost-effectiveness analysis [7].
For evaluation of clinical outcome and cost-effectiveness
of tests, randomized clinical trials (RCTs) are often not
feasible.
We will shortly review each step of diagnostic research
and discuss decision analysis as a useful alternative* Corresponding author. Department of Neurology, University Medical
Center Utrecht, Heidelberglaan 100, PO Box 85500, 3508 GAUtrecht, The
Netherlands. Tel.: þ31-88-755-8600; fax: þ31-30-254-2100.
E-mail address: j.d.schaafsma@umcutrecht.nl (J.D. Schaafsma).
0895-4356/09/$ e see front matter  2009 Elsevier Inc. All rights reserved.
doi: 10.1016/j.jclinepi.2009.01.008methodology for critical assessment of clinical value and
efficient use of resources.2. The hierarchy in diagnostic research
Wewill illustrate the different phases of diagnostic research
following the example of carotid artery stenosis, awell-known
risk factor for stroke. Carotid endarterectomy reduces this risk
in selected patients [9,10]. The standard technique for grading
stenosis used to be digital subtraction angiography (DSA), an
invasive imaging modality. Later on, magnetic resonance an-
giography (MRA) and duplex ultrasound (DUS) were intro-
duced as noninvasive alternatives [11].
2.1. Step 1: Test characteristics
Test characteristics of a diagnostic tool provide informa-
tion on the ability to discriminate between the absence and
the presence of disease. They are expressed in terms of sen-
sitivity, specificity, predictive values, and likelihood ratios.
Sensitivity and specificity are useful in selecting tests,
whereas predictive values provide information on the prob-
ability of disease, given a certain test result [1]. Likelihood
ratios characterize the change in the probability of disease
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 In diagnostic research, decision models form a valu-
able alternative when randomized clinical trials
(RCTs) are infeasible by integrating the best avail-
able evidence.
 Decision-analytic models should be increasingly
used to evaluate clinical outcome including cost-
effectiveness of fast developing diagnostic
techniques.
after completing the test compared with the probability of
disease before completing the test.
Test characteristics should be evaluated in a blinded
cross-sectional study. Each test including a reference test
needs to be performed in all study subjects to enable direct
comparisons of the tests. Furthermore, the study partici-
pants ought to be representative of the target population
[12,13]. In diagnostic tools that require interpretation, intra-
and interobserver variability should also be assessed. In
carotid artery stenosis, test characteristics of MRA and
DUS have been established in a blinded cross-sectional
study with DSA as the reference test [14].
A limitation of assessing test characteristics is dichotomi-
zation of test results, whereas only a few tests yield just
‘‘presence’’ or ‘‘absence’’ of disease as test results. For
continuous and ordinal test results, a threshold needs to be
established to determine whether a result is positive or nega-
tive. Ideally, this positivity criterion should reflect the clinical
impact of false-positive and false-negative results. In case of
carotid stenosis, the consequences of false-positive results,
such as complications of unnecessary treatment, should be
weighed against the consequences ofmissing severe stenosis.
Dichotomization generally leads to loss of information. To
avoid this, likelihood ratios can be used. They represent the
ratio between the likelihood of a particular test result in
patients with a certain disease status and the likelihood of
the same test result in patients without this disease status.
In case of multiple test results, the likelihood ratio can be
calculated for each test result. Subsequently, the probability
of the presence of disease, given a certain test result, can be
calculated starting from the probability of disease before
the test result was known and the likelihood ratio of the per-
taining test result [15,16].
A further limitation of test characteristics is the use of
a ‘‘gold’’ standard to establish a ‘‘true’’ disease status.
Within this framework, a new test can never outperform
its reference test, which in daily practice has frequently
happened. For example, computed tomography (CT) scan-
ning was clearly better than skull radiography for assessing
intracranial pathology.
Moreover, test characteristics are not constant, but are
influenced by factors, such as prevalence of disease, diseaseseverity, gender, age, and comorbidity. The higher the preva-
lence of disease, the higher the predictive value of a positive
test result and the lower the predictive value of a negative test
result. Apart from the predictive values, sensitivity and
specificity may also be influenced by disease prevalence.
However, the latter effect is indirect through prevalence vary-
ingwith disease severity or disease spectrum.The probability
of disease changes when information is obtained from the
history, physical examination, and prior tests, because this
information is used to select patients with a higher probabil-
ity of disease for further diagnostic testing [17].Within a spe-
cific selection of patients, the prevalence of disease and
disease severity may be higher. In case of a more advanced
stage of disease, the sensitivity will increase when abnormal-
ities are easily detected. The relation between prevalence and
clinical setting is illustratedby the comparisonbetweenahos-
pitalized bedridden patient who develops sudden dyspnea
and hypoxia accompanied by an elevated level of d-dimers,
and an otherwise healthy person who presents with acute
dyspnea in an outpatient setting. Clearly, the first patient
has a higher probability of pulmonary embolism than the sec-
ond. Because the first patient was bedridden, more extensive
pulmonary embolism could have been developed than in the
second patient, whichmay increase the likelihood that embo-
lism is detected on subsequent pulmonary CT angiography,
thus increasing sensitivity. Conversely, in a screening setting,
the prevalence of disease is low and disease stages are likely
to be less advanced, which may increase the specificity.
Hence, test characteristics can vary with the population in
which the test is applied. The influence of other factors, such
as age, sex, and comorbidity, on test characteristics can be
evaluated by multivariate regression analysis [18,19].
Although seemingly straightforward, a considerable var-
iation in study design in test research has been observed. To
overcome inconsistent methodology and reporting on test
research, the STARD initiative (Standards for Reporting
of Diagnostic Accuracy) was launched [20].2.2. Step 2: Added value of a test
In clinical practice, tests are generally used in sequence.
For each subsequent test, its added value must be considered.
The added value in this phase of evaluation is expressed in
terms of increase in proportion of patients correctly catego-
rized as diseased or nondiseased, which is represented by
an increased area under the receiver-operating characteristic
(AUROC) curve.
Added value of a new test can be estimated using mul-
tivariate regression analysis [3,8].
In addition, a statistically significant increase in the
AUROC curve does not necessarily represent clinical
improvement, because this also depends on the positivity
criterion. In patients with clinically suspected carotid artery
stenosis, the added value of imaging will not inform us
whether clinical outcome will improve in terms of strokes
avoided. If MRA enables detecting smaller grade stenosis
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When patients with carotid artery stenosis benefit from
treatment of severe stenosis only, which could already be
accurately detected by DUS, detection of smaller grade
stenosis by MRA will not improve outcome. Thus, added
value in terms of a statistically significant increase in
AUROC curve may not always have actual clinical value.2.3. Step 3: Clinical outcome
The eventual goal of a new diagnostic test is to improve
clinical outcome [3e5,8]. Clinical outcome after imple-
mentation of a new diagnostic test can be assessed by an
RCT [2e4,7].
RCTs in diagnostic research, however, have several lim-
itations. Firstly, RCTs generally require a long follow-up
before consequences of false-positive and false-negative
test results become apparent. During this long period of
follow-up, new diagnostic techniques may emerge, which
may outdate the results of the trial before it is completed.
Secondly, large groups of participants are often needed.
When the new and the reference tests do not differ much
in their ability to detect disease, only the limited subset
of subjects with discordant test results carries relevant in-
formation. Dependent on the expected difference in disease
course after diagnosis and ensuing treatment, the overall
difference in outcome between the randomized groups
may be further diluted. Therefore, a straightforward com-
parison of two diagnostic tests may already require many
participants. Importantly, often more than two diagnostic
tests require simultaneous evaluation. Additionally, various
cutoff criteria, including multiple test results, the order of
tests, and specific combinations of tests, will increase the
number of diagnostic strategies to be evaluated. Represent-
ing all diagnostic strategies implies that the number of par-
ticipants required increases exponentially. In the example
of carotid stenosis, test characteristics of DUS, MRA, and
DSA show little difference. An RCT should include ample
participants to represent all relevant diagnostic strategies
and to attain sufficiently large groups with discordant test
results. Finally, a diagnostic RCT including an already es-
tablished treatment strategy is inefficient. If outcome of
treatment has already been established by therapeutic re-
search, follow-up of treated patients would be redundant.
In carotid stenosis, the effect on clinical outcome after
carotid endarterectomy had already been assessed in thera-
peutic trials [9,10]. Therefore, follow-up after treatment
was deemed unnecessary for the evaluation of diagnostic
strategies. An RCT would be a viable option only if the
new diagnostic tool has consequences for treatment that
has not been previously evaluated.
Decision-analytic models present an important alterna-
tive to an RCT [2,5]. Through modeling, clinical outcome
after application of a new test can be predicted by integrat-
ing the available evidence. A decision tree gives an over-
view of all diagnostic strategies with probabilities foreach event. A decision tree will not suffice when events
tend to recur or when events occur after a long and variable
time span, such as in chronic diseases [21,22]. For more
complex diagnostic and disease processes, such as in ca-
rotid artery stenosis, Markov models are useful. These are
typically based on probabilities of transitions between
predefined health states for all possible scenarios. Time-
dependent risks and instantaneous risks for each scenario
can be included. The distribution of patients among the dif-
ferent health states after a specified time span, for example,
1 year, is calculated. This can repeatedly be performed
depending on the defined duration of follow-up. Uncer-
tainty regarding the estimates of the input parameters of
the model can be explored using Monte Carlo simulation.
Through Monte Carlo simulation, multivariable sensitivity
analysis is conducted to predict clinical outcome of a hypo-
thetical group of subjects after a defined period of time,
including uncertainty regarding the predicted outcome
[22e24]. Decision-type models are flexible and can be de-
signed to reflect an infinite number of diagnostic strategies.
Furthermore, models can simulate a long follow-up period
for a large group of subjects while recording all relevant
outcomes and time frames simultaneously. Because there
is no need to perform a lengthy RCT, the duration of uncer-
tainty regarding the best diagnostic strategy is considerably
shortened. Moreover, although decision models may appear
complex and modeler driven, they do not obscure clinical
evidence. All assumptions and estimates can be verified.
The level of decision uncertainty with regard to the ap-
propriate diagnostic strategy is mostly reduced by an RCT.
Decision modeling forms the only alternative where
a proper RCT is unfeasible. Uncertainty remaining after
a modeling study may be reduced by further research on
the parameter that introduces most uncertainty. Whether in-
vestment of additional resources to reduce uncertainty is
worthwhile can be formally assessed [25].
There are some limitations to decision models. To create
the model, sufficient information should be available. Fur-
thermore, diagnostic processes may be too complex to sum-
marize in a decision tree. In addition, decision models may
never comprise all subtle associations and interactions of
clinical reality. For instance, test characteristics are gener-
ally assumed to be constant and independent of other test
results acquired previously. In reality, these previous test
results can influence the interpretation of the subsequent
test as being discussed before, but the actual change in test
characteristics is rarely known. By sensitivity analysis, the
influence of change in test characteristics on the eventual
outcome can be assessed.2.4. Step 4: Cost-effectiveness
Decision models can also keep track of resource use in
relation to clinical outcome. The costs of the tests applied,
the transitions, and events occurring can be integrated in
themodel. Subsequently, the incremental costs per additional
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life-year (QALY) gained, can be calculated for all diagnostic
strategies. By comparing these results, the strategy with the
best trade-off between costs and effects can be identified.
A study comparing 62 diagnostic strategies for carotid
artery stenosis was performed. Using a Markov model,
long-term outcome of the diagnostic work-up and following
treatments in terms of life-years, QALYs, and costs were pre-
dicted and compared across strategies. DUS alone resulted in
an optimal balance between costs and effects. The addition of
MRA led to a slightly better outcomewith a disproportionate
increase in costs. Because of its complication risk, any strat-
egy comprising DSAwas proven inferior [26].
This demonstrates that Markov modeling not only allows
for assessment of cost-effectiveness, but also for evaluation
of clinical outcome.Hence, this example covers steps 3 and 4.3. Evaluation of decision models
Examples of validated decision-analytic models showed
that the results of decision modeling were consistent with
observed data from cohort follow-up studies [27e29]. For
two of these studies, the input parameters of the Markov
model originated from a cohort different from that with
which the results were compared [27,28]. Another study
used the short-term follow-up data of an observational
study cohort for a Markov model. The expected value of
the model was compared with the long-term follow-up data
of the same cohort and with data from the literature [29].
A few aspects are important for the evaluation of Mar-
kov models. First, the model should reflect clinical reality
in sufficient detail such that critical evaluation by expert
peers remains possible. Furthermore, all model compo-
nents, that is, the parameters describing each state transi-
tion, the health state value judgments, and cost estimates,
need to be discussed in a multidisciplinary setting. Finally,
because Markov models will be increasingly used, guide-
lines for its evaluation need to be developed [30,31].
We strongly recommend using decision models to eval-
uate diagnostic tests, provided reliable model parameters
can be obtained, particularly, estimates of key variables.
Notably, a reference standard is required to evaluate any
diagnostic approach, because it remains essential for the
diagnosis of any disease. This reference standard does not
necessarily have to be a ‘‘gold’’ standard. Even though im-
perfection of a reference standard impairs perfect labeling
of ‘‘false’’-positive and ‘‘false’’-negative test results, the
impact of uncertainty of test characteristics on clinical out-
come can be evaluated by Monte Carlo simulation. Finally,
a standard treatment and pertaining outcome should be
established. This can range from supportive treatment to
causal treatment. For most of the diseases, a certain treat-
ment can be recognized. Hence, we believe that, in most
cases, a decision model has major advantages compared
with diagnostic RCTs, because it saves time and resources,
and allows cost-effectiveness analysis.4. Conclusions
Evaluation of a diagnostic strategy requires a phased
approach. For assessment of outcome in addition to test
characteristics frequently, an RCT is neither feasible nor
warranted. Decision-analytic models can integrate the best
available evidence, including economic data, and should be
part of the standard methodology in diagnostic research.Acknowledgments
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